Intervention Review

You have free access to this content

Creatine for treating muscle disorders

  1. Rudolf A Kley1,*,
  2. Mark A Tarnopolsky2,
  3. Matthias Vorgerd3

Editorial Group: Cochrane Neuromuscular Disease Group

Published Online: 5 JUN 2013

Assessed as up-to-date: 11 SEP 2012

DOI: 10.1002/14651858.CD004760.pub4


How to Cite

Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD004760. DOI: 10.1002/14651858.CD004760.pub4.

Author Information

  1. 1

    University Hospital Bergmannsheil, Ruhr University Bochum, Department of Neurology, Bochum, Germany

  2. 2

    McMaster University, Department of Neurology and Rehabilitation, Hamilton, Ontario, Canada

  3. 3

    Kliniken Bergmannsheil, Ruhr University Bochum, Department of Neurology, Bochum, Germany

*Rudolf A Kley, Department of Neurology, University Hospital Bergmannsheil, Ruhr University Bochum, Buerkle-de-la-Camp-Platz 1, Bochum, 44789, Germany. rudolf.kley@rub.de.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 5 JUN 2013

SEARCH

[Figure 1]
Figure 1. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 2]
Figure 2. Forest plot of comparison: 1 Creatine versus placebo, outcome: 1.1 Maximum voluntary contraction (MVC) in muscular dystrophies.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Creatine versus placebo, outcome: 1.2 MVC in metabolic myopathies.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Creatine versus placebo, outcome: 1.3 Global assessment of improvement in muscular dystrophies.
[Figure 5]
Figure 5. Forest plot of comparison: 1 Creatine versus placebo, outcome: 1.4 Neuromuscular Symptoms Score (NSS) in muscular dystrophies.
[Figure 6]
Figure 6. Forest plot of comparison: 1 Creatine versus placebo, outcome: 1.5 Percentage change in MRC sum score in muscular dystrophies.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Creatine versus placebo, Outcome 1 Maximum voluntary contraction (MVC) in muscular dystrophies.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Creatine versus placebo, Outcome 2 MVC in metabolic myopathies.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Creatine versus placebo, Outcome 3 Global assessment of improvement in muscular dystrophies.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Creatine versus placebo, Outcome 4 Neuromuscular Symptoms Score (NSS) in muscular dystrophies.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Creatine versus placebo, Outcome 5 Percentage change in MRC sum score in muscular dystrophies.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Creatine versus placebo, Outcome 6 PCr/beta-ATP ratio in metabolic myopathies.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Creatine versus placebo, Outcome 7 ATP consumption during aerobic exercise in metabolic myopathies.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Creatine versus placebo, Outcome 8 ATP consumption during ischaemic exercise in metabolic myopathies.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Creatine versus placebo, Outcome 9 tau after aerobic exercise in metabolic myopathies.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Creatine versus placebo, Outcome 10 tau after ischaemic exercise in metabolic myopathies.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Creatine versus placebo, Outcome 11 Lean body mass (LBM) in muscular dystrophies.